GENOUROB

GENOUROB develops and manufactures innovative medical devices that focus on spinal and knee health, aiming to enhance diagnostic accuracy for medical professionals. Founded in 2005 and headquartered in Laval, France, GENOUROB specializes in advanced medical devices that assess knee stability. The company has not reported any significant business pivots or changes in operations. GENOUROB has engaged in 2 deals, with the most recent being a Series A funding round on October 8, 2014, where they raised EUR 0.

230 mn led by Go Capital, bringing the total amount raised to EUR 0. 230 mn. The CEO is Stéphane NOUVEAU. GENOUROB specializes in the design, manufacture, and sale of innovative medical devices focused on spinal and knee health.

Their flagship offerings include advanced motorized and computerized arthrometers engineered for precise knee laxity assessment. These devices utilize a patented methodology recognized by scientific communities globally, targeting medical professionals, orthopedic specialists, and rehabilitation centers in Europe, North America, and Asia. GENOUROB generates revenue through the direct sales of its specialized medical devices to healthcare providers, clinics, and hospitals. The company operates primarily on a B2B model, forming partnerships with medical institutions and distributors.

Their pricing strategy supports premium pricing for flagship products, with clients typically engaging in bulk orders or long-term agreements to maintain a steady revenue stream. Following their Series A funding round in October 2014, where they raised EUR 0. 230 mn, GENOUROB plans to utilize this capital to support the development of new products focused on knee health. They are targeting expansion into North American and Asian markets by 2025, aiming to broaden their reach and increase their market share in the medical devices sector.